Biopharma stocks saw plenty of movement in September as investors weighed clinical readouts, financing activity and the likelihood of candidate success across the sector.

Two standouts, Viking Therapeutics’ 24% jump and Longeveron’s 64% plunge, highlight differing ends of the spectrum. Overall, the broader biotech sector was comparatively subdued, with the XBI declining 3.5% for the month.

Here, BioSpace has analyzed these two sizeable stock shifts from last month and the developments driving the activity. This feature is not intended to be a comprehensive review of all public biotech movement.

Who’s hot: Viking Therapeutics (VKTX)

Viking Therapeutics stood out as one of September’s…